GlassScriptPhysician profile
Nadya Edwards
NPI 1649420647
$6,819.48
in general payments reported to CMS, 2019-2025
33 companies · $1,581 in 2025
The $1,581 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,455 · 2022: $1,041 · 2023: $1,663 · 2024: $1,079 · 2025: $1,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,169 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,168.77 |
| Education | $154.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.61 | 2021-2025 | |
| Janssen Biotech, INC. | $870.30 | 2021-2025 | Tremfya, Simponi, Stelara |
| Amgen INC. | $736.52 | 2021-2025 | Otezla, Enbrel, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $480.73 | 2021-2025 | Arazlo, Jublia, Targretin |
| Pfizer INC. | $388.60 | 2021-2024 | |
| Dermavant Sciences, INC. | $371.44 | 2023-2024 | Vtama |
| Incyte Corporation | $354.27 | 2023-2025 | Opzelura, Opzelura |
| Ucb, INC. | $344.84 | 2021-2024 | Bimzelx |
| Leo Pharma INC. | $313.32 | 2023-2025 | Anzupgo, Adbry |
| Sun Pharmaceutical Industries INC. | $311.50 | 2021-2025 | Odomzo, Blu-U |
| Galderma Laboratories, L.P. | $243.98 | 2021-2023 | |
| Merz North America, INC. | $155.51 | 2021-2023 | Xeomin |
| Lilly USA, LLC | $139.45 | 2021-2025 | Ebglyss, Taltz |
| Arcutis Biotherapeutics, INC. | $138.36 | 2023-2025 | Zoryve |
| Genzyme Corporation | $129.05 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $124.09 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $121.88 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $113.60 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $96.64 | 2023 | Sotyktu |
| Allergan, INC. | $74.29 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $55.39 | 2021 | |
| Botanix Sb INC | $54.88 | 2025 | Sofdra |
| Almirall LLC | $44.62 | 2022 | |
| Krystal Biotech INC | $30.81 | 2023 | Vyjuvek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.99 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $24.35 | 2024 | Ycanth |
| Lnhc, INC | $22.18 | 2025 | Zelsuvmi |
| Novartis Pharmaceuticals Corporation | $20.39 | 2022 | |
| Dermira, INC. | $19.85 | 2021 | |
| Musculoskeletal Transplant Foundation INC. | $16.49 | 2021 | |
| Qiagen, LLC | $16.47 | 2022 | |
| Kyowa Kirin, INC. | $15.61 | 2021 | |
| Epi Health, LLC | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadya Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.